|
|
|
|
 |
| January 12, 2012 | ISSUE NUMBER 233 VOL 8 |
|
Drug Development
Calculating the Cost of R&D: Defending Tufts Research
Estimates of what it takes to deliver a compound to market are more than an academic exercise—such data has an increasingly important on-the-ground impact on industry revenues, because if you cannot justify your costs how do you expect to prevail on price? ...Read More
C-Suite
Humana CEO: Keep People Out of Hospitals
Outgoing CEO Michael McCallister tells an audience at the 30th Annual JP Morgan Healthcare conference that one of Humana’s primary strategies is to keep patients out of hospitals and other healthcare institutions ...Read More
Commentary
The Rising Clout of the Patient
In 2011, the patient’s clout as a stakeholder was firmly established, as reflected in several industry conferences. How will this grow in 2012? ...Read More
Healthcare
My Healthcare's Better than Your Healthcare
Long before the current debate on healthcare started, there was a different war brewing. For decades, people have been fighting over which program and plan is best: healthcare provided to government workers, military personnel, or civilians? ...Read more
Ad Stars 2012
Call for Entries
It’s that time again for the editors of Pharm Exec to narrow down its choices for our annual Ad Stars feature, recognizing the most clever, unique, and effective campaigns in pharma advertising over the past year. We’d like to extend an opportunity for you to submit an ad for consideration. Please feel free to share with us the campaign that your firm or agency feels truly helps the client stand apart from its competition ...For more information |
|
|
 // Premier Research Group (Philadelphia) announced the appointment of Susan C. Stansfield, PhD, to the position of Executive Vice President, Clinical Development.
// Dicerna Pharmaceuticals (Watertown, Mass.) appointed James B. Weissman to Chief Business Officer. // Harlan Laboratories (Indianapolis) announced that Doug Vaughan has been recruited as Chief Financial Officer and David Broecker will join the company as President, Research Models & Services. // John Varian was appointed Chief Executive Officer by XOMA Corp.'s (Berkeley, Calif.) Board of Directors. // The COPD Foundation appointed Dave Barringer as its new Executive Director. // Isotechnika Pharma (Edmonton, Alberta, Canada) announced a number of changes to its senior management and Board of Directors. Daniel Park has resigned as Chief Business Officer, although he remains a Director of the company. Dr. Robert Foster has relinquished the title of Chairman of the Board to Dr. Peter Wijngaard of Duggingen, Switzerland. Dr. Foster remains Chief Executive Officer and a Director of the company.
|
|
|
|
|
|
|
 |
 |
|
| |
 |
 |
|
 |
In your opinion, how likely is it that pharma and biotech companies will continue to increase their outsourcing of clinical trials and related drug development in the next five years?
|
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To
ensure delivery to your Inbox, please add us to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
